Kuryltsiv Nadiya B, Halei Kateryna M
Danylo Halytsky Lviv National Medical University, Ophthalmology Department, Lviv, Ukraine.
Wiad Lek. 2019;72(4):716-722.
Introduction: Autoimmune uveitis (AU) is an inflammation of the uvea due to an autoimmune reaction to self-antigens. There are no standardized treatment protocols for AU. A new class of drugs called biologics, that target the various mediators of the inflammation cascade, may potentially provide more effective and less toxic corticosteroids treatment of AU. The aim: The aim of this review was to make the evaluatation of the interleukins influence on intraocular inflammation in available literature and summarize the expediency of using anti-interleukins agent in case of AU.
Material and methods: This article is a review and summary of the up-to-date results of pivotal experimental and clinical trials targeting the Interleukins (IL), including IL-6, IL-10, IL-17, IL-22, IL-23, and tumor necrosis factor alpha (TNF-α). Also reviews focus on the potential use of anti-interleukin therapy for the treatment of autoimmune diseases (AD).
Conclusions: AU is an inflammation of the uvea due to an autoimmune reaction to self-antigens. The most important IL in the pathogenesis of AU are IL-6, IL-10, IL-17, IL-22, IL-23 and TNF-α. Anti-interleukin therapy is partially described. Future randomized controlled trials are urgently needed to be conduct.
介绍：自身免疫性葡萄膜炎（AU）是因对自身抗原产生自身免疫反应而导致的葡萄膜炎症。目前尚无针对AU的标准化治疗方案。一类名为生物制剂的新型药物，可靶向炎症级联反应的各种介质，可能为AU提供更有效且毒性更小的皮质类固醇治疗。目的：本综述的目的是评估白细胞介素对现有文献中眼内炎症的影响，并总结在AU病例中使用抗白细胞介素药物的合理性。
材料与方法：本文是对针对白细胞介素（IL），包括IL-6、IL-10、IL-17、IL-22、IL-23和肿瘤坏死因子α（TNF-α）的关键实验和临床试验最新结果的综述与总结。综述还聚焦于抗白细胞介素疗法在自身免疫性疾病（AD）治疗中的潜在应用。
结论：AU是因对自身抗原产生自身免疫反应而导致的葡萄膜炎症。AU发病机制中最重要的白细胞介素是IL-6、IL-10、IL-17、IL-22、IL-23和TNF-α。抗白细胞介素疗法已有部分描述。迫切需要开展未来的随机对照试验。
